Shingles ZOSTER Vaccine Study

Shingles (Herpes Zoster) is a painful skin rash that may lead to complications such as long-lasting nerve pain, known as post-herpetic neuralgia (PHN). It is caused by the same virus that causes chickenpox – and it can reactivate later in life.

People 70 years of age and older are at higher risk for shingles and its complications. Although there is an approved vaccine, researchers are working to develop new options that may improve protection and reduce side effects. T

his study is evaluating an investigational vaccine combining a viral protein with an immune-stimulating ingredient. Researchers are comparing the investigational vaccine to Shingrix (an existing and approved shingles vaccine) to see:

• How safe it is
• How well it stimulates the immune system
• Whether it helps prevent shingles and associated complications (i.e., PHN) in older adults

Participants will be randomly assigned to receive:

• The investigational vaccine
• Shingrix (an approved shingles vaccine) 

You will receive two vaccine doses and return for follow-up visits over the next year. The vaccine will be administered as an intramuscular injection.

After each vaccination, you’ll be given a symptom diary, a thermometer, and a small ruler. For 7 days after each dose, you will be asked to record any symptoms or reactions, such as redness or swelling at the injection site, fever, or general discomfort.

Our trained medical study team will closely monitor your health, track side effects, and take blood samples to measure immune response.

Why join this clinical research study?

• Gain early access to new potential vaccines at no cost 
• Contribute to research that may help benefit others like you
• Receive health checks and advice from our professional medical team

Your privacy is important. All personal information will be kept strictly confidential. Register your interest today.